

AMENDMENTS TO THE CLAIMS

1. **(Currently amended)** An isolated polynucleotide ~~which contains a base sequence identical or at least 95% homologous to that represented by SEQ ID NO: 2 or SEQ ID NO: 6~~ comprising a nucleotide sequence selected from the group consisting of the nucleotide sequence of SEQ ID NO: 6 and a nucleotide sequence which encodes the amino acid sequence of SEQ ID NO: 5.

2. **(Currently amended)** An isolated polynucleotide comprising a nucleotide sequence which hybridizes under high stringent conditions to the nucleotide sequence of SEQ ID NO: 6, wherein the high stringent conditions comprise a sodium concentration at about 19 mM and a temperature at about 65 °C ~~to a base sequence represented by SEQ ID NO: 2 or SEQ ID NO: 6.~~

3. **(Original)** The isolated polynucleotide according to claim 1 or 2, wherein the polynucleotide is a DNA.

4. **(Cancelled)**

5. **(Withdrawn)** The isolated polynucleotide according to claim 1 or 2, wherein the polynucleotide is an antisense polynucleotide.

6. **(Withdrawn)** The isolated polynucleotide according to claim 5, wherein the antisense polynucleotide is RNA.

7. **(Currently amended)** An agent, which comprises the polynucleotide according to claim 1 or 2.

8. **(Currently amended)** The agent according to claim 7, which is for diagnosis of ~~diseases~~ cancer associated with expression of the polynucleotide, which encodes the protein ~~containing~~ comprising the amino acid sequence ~~represented by~~ of ~~SEQ ID NO: 1 or~~ SEQ ID NO: 5.

9. **(Currently amended)** The agent according to claim 7, which is for treatment of ~~diseases~~ cancer associated with expression of the polynucleotide, which encodes the protein ~~containing~~ comprising the amino acid sequence ~~represented by~~ of ~~SEQ ID NO: 1 or~~ SEQ ID NO: 5.

10. **(Withdrawn)** A method for diagnosis of diseases associated with expression of the polynucleotide, which encodes the protein containing the amino acid sequence represented by SEQ ID NO: 1 or SEQ ID NO: 5, wherein the method comprises using the polynucleotide according to claim 1 or 2.

11. **(Withdrawn)** A method for treatment of diseases associated with expression of the polynucleotide, which encodes the protein containing the amino acid sequence represented by SEQ ID NO: 1 or SEQ ID NO: 5, wherein the method comprises using the polynucleotide according to claim 1 or 2.

12. **(Withdrawn)** An agent, which comprises the polynucleotide according to claim 6.

13. **(Withdrawn)** The agent according to claim 12, which is for diagnosis of diseases associated with expression of the polynucleotide, which encodes the protein containing the amino acid sequence represented by SEQ ID NO: 1 or SEQ ID NO: 5.

14. (Withdrawn) The agent according to claim 12, which is for treatment of diseases associated with expression of the polynucleotide, which encodes the protein containing the amino acid sequence represented by SEQ ID NO: 1 or SEQ ID NO: 5.

15. (Withdrawn) A method for diagnosis of diseases associated with expression of the polynucleotide, which encodes the protein containing the amino acid sequence represented by SEQ ID NO: 1 or SEQ ID NO: 5, wherein the method comprises using the polynucleotide according to claim 5.

16. (Withdrawn) A method for treatment of diseases associated with expression of the polynucleotide, which encodes the protein containing the amino acid sequence represented by SEQ ID NO: 1 or SEQ ID NO: 5, wherein the method comprises using the polynucleotide according to claim 5.

17. (Currently amended) A recombinant vector, ~~which contains~~ comprising the polynucleotide according to claim 1 or 2.

18. (Currently amended) An isolated transformant, which is transformed by the recombinant vector according to claim 17.

19. (Withdrawn) A method for screening a compound or its salt that alters the binding property between a ligand and a protein encoded by the polynucleotide according to claim 1 or 2, which comprises using the protein encoded by the polynucleotide according to claim 1 or 2.